Giuseppa Ferraro

TL;DR: A comprehensive review of the major progresses reported so far in the EGFR inhibition in this molecularly-selected subgroup of NSCLC patients, from the early successes with first generation EGFR TKIs, Erlotinib and Gefitinib, to the novel irreversible and mutant-selective inhibitors and ultimately the emerging challenges that the authors, in the next future, are called to deal with.

TL;DR: The aim of this article is to provide an overview of the role of HER2 dysregulation in NSCLC, trying to throw a light not only on the strengths but also the weaknesses of the studies conducted so far, generating a growing interest upon this oncogenic driver.

TL;DR: The data suggest that the combination of AR and E-cadherin expression as well as Ki-67 status might be useful prognostic markers in TNBC and could play an interesting role to classify subgroups of TNBC.

TL;DR: Paclitaxel plus cisplatin combination is an active regimen with an acceptable safety profile in recurrent/metastatic HNSCC and is a valid alternative to infusional fluorouracil (5FU)/cisplatin, according to the opinion.

TL;DR: Patients should benefit from continued trastuzumab therapy, as shown by the maintenance of (TTP) even beyond second-line treatment.